168 related articles for article (PubMed ID: 37951309)
21. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
Tsoi LC; Hacini-Rachinel F; Fogel P; Rousseau F; Xing X; Patrick MT; Billi AC; Berthier CC; Kahlenberg JM; Lazzari A; Wiegmann H; Ständer S; Piketty C; Julia V; Krishnaswamy JK; Gudjonsson JE
J Allergy Clin Immunol; 2022 Apr; 149(4):1329-1339. PubMed ID: 34857395
[TBL] [Abstract][Full Text] [Related]
22. Dupilumab for the treatment of prurigo nodularis: A systematic review.
Cao P; Xu W; Jiang S; Zhang L
Front Immunol; 2023; 14():1092685. PubMed ID: 36742321
[TBL] [Abstract][Full Text] [Related]
23. Learning from nemolizumab: A promising therapy for prurigo nodularis.
Kim BS
J Allergy Clin Immunol; 2024 Jun; 153(6):1548-1549. PubMed ID: 38460679
[No Abstract] [Full Text] [Related]
24. [Prurigo nodularis: its association with dermatoses and systemic disorders].
Mettang T; Vonend A; Raap U
Hautarzt; 2014 Aug; 65(8):697-703. PubMed ID: 25113328
[TBL] [Abstract][Full Text] [Related]
25. [THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].
Murakami Y; Sugiyama A; Ideguchi H; Murakami Y; Amimoto Y; Nishie H; Odajima H
Arerugi; 2020; 69(3):213-217. PubMed ID: 32435023
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab for pediatric prurigo nodularis: A case report.
Fachler T; Maria Faitataziadou S; Molho-Pessach V
Pediatr Dermatol; 2021 Jan; 38(1):334-335. PubMed ID: 33247435
[TBL] [Abstract][Full Text] [Related]
27. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
28. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
Tanis R; Ferenczi K; Payette M
J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
[TBL] [Abstract][Full Text] [Related]
29. Impact of Itch on Sleep Disturbance in Patients with Prurigo Nodularis.
Gwillim EC; Nattkemper L; Yosipovitch G
Acta Derm Venereol; 2021 Mar; 101(3):adv00424. PubMed ID: 33704503
[No Abstract] [Full Text] [Related]
30. [Prurigo nodularis].
Misery L
Rev Prat; 2020 Feb; 70(2):187-189. PubMed ID: 32877138
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Dupilumab in Pediatric Patient With Prurigo Nodularis-Like Atopic Dermatitis.
Yiling Y; Ali K; Jiayang D; Qiu Y; Kai G; JinPeng S; Tianci X; Min C; Menghua L; Liming W
Dermatitis; 2023; 34(2):162-163. PubMed ID: 36917530
[No Abstract] [Full Text] [Related]
32. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
33. Use of Isoquercetin in the Treatment of Prurigo Nodularis.
Pennesi CM; Neely J; Marks AG; Basak SA
J Drugs Dermatol; 2017 Nov; 16(11):1156-1158. PubMed ID: 29141065
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.
Napolitano M; Fabbrocini G; Scalvenzi M; Nisticò SP; Dastoli S; Patruno C
Dermatitis; 2020; 31(1):81-84. PubMed ID: 31517666
[TBL] [Abstract][Full Text] [Related]
35. Prurigo Nodularis: Review and Emerging Treatments.
Leis M; Fleming P; Lynde CW
Skin Therapy Lett; 2021 May; 26(3):5-8. PubMed ID: 34077168
[TBL] [Abstract][Full Text] [Related]
36. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.
Pezzolo E; Gambardella A; Guanti M; Bianchelli T; Bertoldi A; Giacchetti A; Donini M; Argenziano G; Naldi L
J Am Acad Dermatol; 2023 Aug; 89(2):430-432. PubMed ID: 37150301
[No Abstract] [Full Text] [Related]
37. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
38. Nemolizumab: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(10):1143-1150. PubMed ID: 35834124
[TBL] [Abstract][Full Text] [Related]
39. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
40. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
